Compliance
This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.
Key progressives in the House and Senate have revived the fight in Congress over "Medicare for All," a single-payer health system based on the Medicare program.
A House Energy and Commerce Committee health markup on Wednesday offered more evidence that price transparency and pharmacy benefit manager regulation are two issues that have enough bipartisan support to move ahead in this Congress. Among the measures the panel advanced on a unanimous 27-0 vote: Codifying and strengthening Trump-era rules for hospitals and insurers to make ...
The Federal Trade Commission issued a warning Thursday about companies’ use of consumers’ biometric information such as facial recognition technology, saying it raises “significant consumer privacy and data security concerns.” Why it matters: The warning comes as a growing number of companies amass data based on individuals’ physiological features which could be used to infer consumers’ health or ...
A federal appeals court Monday partially paused a ruling from a Texas district court judge that jeopardized access to free preventive care for 150 million Americans.
A key Senate panel advanced a package of bipartisan bills aimed at improving generic drug competition and reforming the business practices of pharmacy benefit managers (PBMs).
The U.S. government on Thursday will end the COVID-19 Public Health Emergency that allowed millions of Americans to receive vaccines, tests and treatments at no cost. The emergency is also tied to telehealth flexibilities, Medicaid enrollment safeguards, and the ability of government health agencies to collect data on the spread of the coronavirus.
Some of the world’s biggest drugmakers are laying legal groundwork to fight the U.S. plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights, according to six industry sources. The Biden Administration’s signature drug pricing reform, part of the Inflation Reduction ...
As the expiration of the Covid-19 public health emergency declaration approaches, the US Drug Enforcement Administration has extended the flexibilities regarding the prescription of controlled medications via telehealth. Before the pandemic, medical practitioners were subject to the conditions of the Ryan Haight Act, which required at least one in-person medical examination before prescribing a controlled medicine, ...
Spring heralds the start of rate review season: that time of year when state departments of insurance assess health insurers’ proposed rates for the next year and determine whether their plans comply with federal and state laws. Many state insurance departments now have a new responsibility as part of that process
The Drug Enforcement Administration has asked the White House for more time to finalize draft rules that proposed reinstating stricter limits requiring doctors to evaluate patients in-person before prescribing certain drugs — like Adderall and opioid use disorder treatment — via telehealth. Driving the news: DEA administrator Anne Milgram said on Wednesday that temporarily keeping the pandemic-era flexibilities in place would allow ...